NewsSun Pharmaceutical Receives Promoter Group Reclassification Requests Totalling 1.80% ShareholdingSun Pharmaceutical Receives Promoter Group Reclassification Requests Totalling 1.80% Shareholding
Sun Pharmaceutical Industries Limited disclosed on 14 May 2026 that it received requests from three Promoter Group members — Mr. Sudhir Vrundavandas Valia (1,43,45,019 shares; 0.60%), Mrs. Raksha Sudhir Valia (2,88,30,352 shares; 1.20%), and Mrs. Krishna Vrundavandas Valia — seeking reclassification to the 'Public' shareholder category under SEBI Listing Regulations. The combined disclosed shareholding of the applicants stands at 4,31,75,371 shares, representing 1.80% of total shares. The requests are subject to Board of Directors' approval and completion of the prescribed regulatory process before submission to stock exchanges.
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries Limited has informed stock exchanges that it received requests on 14 May 2026 from three members of its Promoter Group seeking reclassification of their shareholder category from 'Promoter Group' to 'Public' under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with Regulation 30 and Regulation 31A of the Listing Regulations.
Shareholders Seeking Reclassification
The three individuals who have submitted reclassification requests are Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia. The table below details the shareholding of each applicant as disclosed in the intimation:
| Shareholder: | No. of Shares Held | Percentage (%) of Shares Held |
|---|---|---|
| Mr. Sudhir Vrundavandas Valia | 1,43,45,019 | 0.60% |
| Mrs. Raksha Sudhir Valia | 2,88,30,352 | 1.20% |
| Mrs. Krishna Vrundavandas Valia | - | - |
| Total | 4,31,75,371 | 1.80% |
Mrs. Krishna Vrundavandas Valia's shareholding details were not disclosed in the intimation.
Regulatory Process and Next Steps
The company has stated that the reclassification requests will be examined in accordance with the applicable provisions of the Listing Regulations. Upon completion of the examination, the requests will be placed before the Board of Directors for its consideration. Subject to Board approval and completion of the prescribed regulatory process, Sun Pharmaceutical will take necessary steps, including submission of the application to the stock exchanges.
The intimation was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983), and was digitally authenticated on 14 May 2026.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.69% | +0.30% | +12.32% | +6.81% | +9.16% | +168.38% |
How might the reclassification of 1.80% promoter group shares to public category affect Sun Pharmaceutical's overall promoter holding threshold and corporate governance dynamics?
Could the Valia family's reclassification signal a broader restructuring of Sun Pharmaceutical's promoter group, and might other promoter group members follow suit?
What impact could this reclassification have on Sun Pharmaceutical's stock liquidity and free float, potentially attracting new institutional investors or index rebalancing?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
